Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.34 +6.2%	$2.70	$1.05 ▼ $4.13	$331.66M	1.89	596,153 shs	621,748 shs
LGND Ligand Pharmaceuticals	$126.92 +4.3%	$109.40	$90.29 ▼ $129.90	$2.45B	0.84	116,742 shs	140,898 shs
MCRB Seres Therapeutics	$14.85 +18.1%	$8.51	$6.53 ▼ $30.60	$129.64M	2.75	133,661 shs	739,585 shs
PRAX Praxis Precision Medicines	$53.60 +6.1%	$42.08	$26.70 ▼ $91.83	$1.09B	2.6	368,770 shs	418,208 shs
STOK Stoke Therapeutics	$12.06 +1.7%	$10.70	$5.35 ▼ $16.15	$658.48M	1.14	674,620 shs	488,258 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+5.82%	+23.85%	-7.50%	+179.83%	-12.46%
LGND Ligand Pharmaceuticals	+4.29%	+11.57%	+12.82%	+18.84%	+27.67%
MCRB Seres Therapeutics	+18.14%	+36.87%	+98.00%	+60.71%	-30.61%
PRAX Praxis Precision Medicines	+6.05%	+14.82%	+20.99%	+80.65%	+5.35%
STOK Stoke Therapeutics	+1.69%	+3.17%	+4.60%	+55.61%	-15.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	1.5511 of 5 stars	3.5	1.0	0.0	1.3	0.8	0.6
LGND Ligand Pharmaceuticals	4.0848 of 5 stars	2.5	1.0	4.4	2.0	3.3	1.9
MCRB Seres Therapeutics	3.4917 of 5 stars	2.9	1.0	4.6	3.8	0.8	0.0
PRAX Praxis Precision Medicines	2.2686 of 5 stars	4.4	1.0	0.0	1.6	1.7	0.0
STOK Stoke Therapeutics	4.1495 of 5 stars	3.7	1.0	4.8	2.3	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	131.76% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$147.17	15.95% Upside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	396.07% Upside
PRAX Praxis Precision Medicines	2.78	Moderate Buy	$94.11	75.58% Upside
STOK Stoke Therapeutics	3.33	Buy	$24.75	105.22% Upside

Current Analyst Ratings Breakdown

Latest STOK, LGND, ADCT, MCRB, and PRAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$97.00 ➝ $115.00
7/1/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00
6/12/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/2/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$97.00
5/15/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
5/14/2025	STOK Stoke Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$47.00 ➝ $35.00
5/9/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$142.00 ➝ $145.00
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$70.84M	4.68	N/A	N/A	($2.10) per share	-1.59
LGND Ligand Pharmaceuticals	$181.49M	13.49	$1.68 per share	75.74	$43.95 per share	2.89
MCRB Seres Therapeutics	$126.32M	1.03	N/A	N/A	$1.61 per share	9.22
PRAX Praxis Precision Medicines	$8.55M	127.70	N/A	N/A	$23.90 per share	2.24
STOK Stoke Therapeutics	$36.56M	18.01	N/A	N/A	$4.32 per share	2.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.45	N/A	N/A	N/A	-197.64%	N/A	-45.57%	8/5/2025 (Estimated)
LGND Ligand Pharmaceuticals	-$4.03M	-$7.12	N/A	34.21	N/A	-73.07%	-7.83%	-6.92%	8/5/2025 (Estimated)
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-41,084.76%	-55.87%	8/12/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$10.72	N/A	N/A	N/A	-2,137.48%	-50.42%	-46.74%	8/12/2025 (Estimated)
STOK Stoke Therapeutics	-$88.98M	$0.79	15.27	N/A	N/A	26.33%	19.08%	15.72%	8/6/2025 (Estimated)

Latest STOK, LGND, ADCT, MCRB, and PRAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MCRB Seres Therapeutics	-$2.72	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	PRAX Praxis Precision Medicines	-$3.40	N/A	N/A	N/A	$0.16 million	N/A
8/6/2025	Q2 2025	STOK Stoke Therapeutics	-$0.0905	N/A	N/A	N/A	$31.51 million	N/A
8/5/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	N/A	N/A	N/A	$17.82 million	N/A
8/5/2025	Q2 2025	LGND Ligand Pharmaceuticals	$1.54	N/A	N/A	N/A	$43.87 million	N/A
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A
5/2/2025	Q1 2025	PRAX Praxis Precision Medicines	-$3.20	-$3.29	-$0.09	-$3.29	$0.20 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.46	4.16
LGND Ligand Pharmaceuticals	N/A	5.27	5.02
MCRB Seres Therapeutics	N/A	2.11	2.11
PRAX Praxis Precision Medicines	N/A	8.44	8.44
STOK Stoke Therapeutics	N/A	8.41	8.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
LGND Ligand Pharmaceuticals	91.28%
MCRB Seres Therapeutics	59.34%
PRAX Praxis Precision Medicines	67.84%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
LGND Ligand Pharmaceuticals	7.00%
MCRB Seres Therapeutics	4.70%
PRAX Praxis Precision Medicines	2.70%
STOK Stoke Therapeutics	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	99.18 million	93.82 million	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.94 million	Optionable
MCRB Seres Therapeutics	330	8.73 million	8.32 million	Optionable
PRAX Praxis Precision Medicines	110	20.37 million	19.82 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	49.41 million	Optionable

STOK, LGND, ADCT, MCRB, and PRAX Headlines

Recent News About These Companies

The charming Stoke-on-Trent four-bed family home that's 'ready to be lived in'

July 13 at 9:30 PM | msn.com

New Royal Stoke technology cuts hospital stays by over a day

July 13 at 9:30 PM | msn.com

Stoke City Boss Delighted To Finally Get Signing Over The Line

July 13 at 6:47 AM | therealefl.co.ukT

Grit bin raiders and double parking hinders work to keep Stoke-on-Trent moving in winter

July 13 at 6:47 AM | msn.com

Five of the best beer gardens around Stoke-on-Trent to enjoy in the sun

July 13 at 6:47 AM | msn.com

Man City prospect told to gain notoriety at Stoke City

July 13 at 6:47 AM | msn.com

Case builds for Biogen, Stoke's Dravet syndrome drug

July 11, 2025 | pharmaphorum.comP

Lille rival Aston Villa in race for Stoke’s Sol Sidibé

July 10, 2025 | sports.yahoo.com

Aston Villa want Stoke City midfielder Sol Sidibe

July 10, 2025 | sports.yahoo.com

Stoke City vs Shrewsbury LIVE Score Updates: Match Canceled

July 10, 2025 | vavel.comV

Council still against Stoke-on-Trent 'merger' as devolution decision gets nearer

July 10, 2025 | msn.com

Live updates after 'accident' on Stoke-on-Trent road

July 10, 2025 | stokesentinel.co.ukS

Stoke City close in on fourth summer signing

July 10, 2025 | msn.com

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

July 10, 2025 | globenewswire.com

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

July 10, 2025 | businesswire.com

Live updates as firefighters on scene of Stoke-on-Trent blaze

July 8, 2025 | stokesentinel.co.ukS

Police helicopter tracks 4 masked kids on stolen motorbikes in Stoke-on-Trent park

July 8, 2025 | msn.com

Stoke-on-Trent firm collapses into administration

July 8, 2025 | msn.com

Driver dies in Royal Stoke after hitting tree

July 8, 2025 | msn.com

Stoke City move early for 'lethal' rising Manchester City star in second signing of the day

July 7, 2025 | msn.com

Stoke Therapeutics' (STOK) "Buy" Rating Reaffirmed at Needham & Company LLC

July 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK, LGND, ADCT, MCRB, and PRAX Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.34 +0.19 (+6.16%)

Closing price 07/14/2025 03:59 PM Eastern

Extended Trading

$3.32 -0.03 (-0.78%)

As of 04:00 AM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Ligand Pharmaceuticals NASDAQ:LGND

$126.92 +5.22 (+4.29%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$126.83 -0.09 (-0.07%)

As of 07/14/2025 05:20 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Seres Therapeutics NASDAQ:MCRB

$14.85 +2.28 (+18.14%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$14.84 0.00 (-0.03%)

As of 04:00 AM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Praxis Precision Medicines NASDAQ:PRAX

$53.60 +3.06 (+6.05%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$52.22 -1.38 (-2.57%)

As of 07/14/2025 07:54 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Stoke Therapeutics NASDAQ:STOK

$12.06 +0.20 (+1.69%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$12.06 0.00 (-0.01%)

As of 07/14/2025 07:32 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time